Sudha Desai
YOU?
Author Swipe
View article: Real-World Concordance between Germline and Tumour BRCA1/2 Status in Epithelial Ovarian Cancer
Real-World Concordance between Germline and Tumour BRCA1/2 Status in Epithelial Ovarian Cancer Open
Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able t…
View article: Predicting the likelihood of a <i>BRCA1/2</i> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer
Predicting the likelihood of a <i>BRCA1/2</i> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer Open
Aims Clinical guidelines recommend testing both germline and tumour DNA for BRCA1/2 pathogenic variants (PVs) in non-mucinous high-grade epithelial ovarian cancer (NMEOC). In this study, we show that some tumour BRCA1/2 PVs are highly like…
View article: Extrauterine Mesonephric-like Neoplasms
Extrauterine Mesonephric-like Neoplasms Open
Mesonephric-like adenocarcinomas (MLA) are rare neoplasms arising in the uterine corpus and ovary which have been added to the recent 2020 World Health Organization Classification of Female Genital Tumors. They have similar morphology and …
View article: Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes
Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes Open
Background Epithelial ovarian cancer (OC) is a heterogenous disease consisting of five major histologically distinct subtypes: high-grade serous (HGSOC), low-grade serous (LGSOC), endometrioid (ENOC), clear cell (CCOC) and mucinous (MOC). …
View article: Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models
Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models Open
Background Patients with ovarian cancer often present at advanced stage and, following initial treatment success, develop recurrent drug-resistant disease. PARP inhibitors (PARPi) are yielding unprecedented survival benefits for women with…
View article: Additional file 1 of Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes
Additional file 1 of Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes Open
Additional file 1. Table S1 (Cell line annotations); Table S2 (Patient demographics); Table S3 (References for subtype mutations).